ライフサイエンスコーパス: tazobactam

1 compared to vancomycin without piperacillin/tazobactam.

2 atients receiving perioperative piperacillin-tazobactam.

3 rom 1.4 for colistin to 4.9 for piperacillin-tazobactam.

4 antibiotics were vancomycin and piperacillin/tazobactam.

5 es) infusions of carbapenems or piperacillin/tazobactam.

6 n bottles with trough levels of piperacillin-tazobactam.

7 fer resistance to the ss-lactamase inhibitor tazobactam.

8 re directly the turnover number of SHV-1 and tazobactam.

9 chanism of inhibition of the GES-2 enzyme by tazobactam.

10 e not significantly different than those for tazobactam.

11 t being released from the enzyme compared to tazobactam.

12 d 50 and 50%, respectively, for piperacillin-tazobactam.

13 third day of administration of piperacillin-tazobactam.

14 ety and tolerability profile to piperacillin/tazobactam.

15 232 of 304 (76.2) treated with piperacillin/tazobactam.

16 isms showed improvement over clinically used tazobactam.

17 of the 193 (81.2%) treated with piperacillin/tazobactam.

18 a-lactamase inhibitors, clavulanic acid, and tazobactam.

19 by only 17% for clavulanic acid and 40% for tazobactam.

20 d resistance to ceftazidime and piperacillin-tazobactam.

21 ime but remained susceptible to piperacillin-tazobactam.

22 ission and received cefepime or piperacillin-tazobactam.

23 increased CDI risk relative to piperacillin/tazobactam.

24 concentrations of cefazolin and piperacillin-tazobactam.

25 O trial was less pronounced for piperacillin/tazobactam.

26 tients with cIAI received either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 h

27 tive (1.45 A) and the inhibited complex with tazobactam (1.65 A).

28 High-dose cefepime-tazobactam (1:1; WCK 4282), a novel antibacterial combin

29 em, 3.8-fold for piperacillin, 10.5-fold for tazobactam, 1.9-fold for vancomycin, and 3.9-fold for ci

30 porins, 31%; trimethoprim, 20%; piperacillin-tazobactam, 11%; chloramphenicol, 9%; and aminoglycoside

31 (74.4-204.0)/3.8 (3.4-21.8) for piperacillin/tazobactam, 12.0 (9.8-16.0) for vancomycin, and 3.7 (3.0

32 (false-susceptible) errors for piperacillin-tazobactam (19 to 27%).

33 8 microg/ml versus 2 microg/ml; piperacillin-tazobactam, 256 microg/ml versus 4 microg/ml; and ticarc

34 eftazidime (25/201 [12.4%]) and piperacillin-tazobactam (28/332 [8.4%] (P = .007).

35 g once a day was equivalent to piperacillin/tazobactam 3.375 g every 6 hours in the treatment of a r

36 ertapenem (1 g daily; n=295) or piperacillin/tazobactam (3.375 g every 6 h; n=291) given for a minimu

37 mg q24 hours) or comparator (IV piperacillin-tazobactam [3.0/0.375 g q6 hours] +/- PO amoxicillin-cla

38 e to cefepime (29.0% vs. 7.0%), piperacillin/tazobactam (31.9% vs. 11.5%), carbapenems (20.0% vs. 2.5

39 ebactam 500 mg/500 mg/250 mg or piperacillin/tazobactam 4 g/500 mg, intravenously every 6 hours for 7

40 s, ceftazidime 2 g every 8 hrs, piperacillin/tazobactam 4.5 g every 6 hrs and 3.375 g every 6 hrs, ce

41 re randomly assigned to receive piperacillin/tazobactam (4.5 g intravenously every 8 hours) with or w

42 im, 45% (95% CI, 0.22 to 0.74); piperacillin-tazobactam, 42% (95% CI, 0.20 to 0.71); and augmentin, 3

43 patients than those who received ceftolozane/tazobactam (72% vs 15%, P < .001).

44 5, 10.8%; 95% CI, 10.1%-11.5%), piperacillin-tazobactam (788, 10.3%; 95% CI, 9.6%-11.0%), and levoflo

45 vailable with susceptibility to piperacillin/tazobactam 94% and meropenem 100%.

46 apenem and the 219 who received piperacillin/tazobactam (94%vs 92%, respectively; between treatment d

47 method, SHV-1, a class A beta-lactamase, and tazobactam, a commercially available beta-lactamase inhi

48 essed the efficacy and safety of ceftolozane-tazobactam, a novel antibacterial with Gram-negative act

49 Ceftolozane/tazobactam, a novel antimicrobial therapy, is active aga

50 f SHV-1 beta-lactamase were inactivated with tazobactam, a potent class A beta-lactamase inhibitor.

51 ctivities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases

52 erated, and more effective than piperacillin/tazobactam alone in febrile, high-risk, neutropenic hema

53 methoxazole, ciprofloxacin, and piperacillin-tazobactam also showed reasonable activity; vancomycin s

54 foxitin, ceftriaxone, cefepime, piperacillin-tazobactam, ampicillin, oxacillin, gentamicin, and a com

55 y both methods to piperacillin, piperacillin-tazobactam, ampicillin-sulbactam, ticarcillin-clavulanat

56 efepime (+/- metronidazole) and piperacillin-tazobactam and a clinical prediction rule to guide anti-

57 strated previously that the reaction between tazobactam and a deacylation deficient variant of SHV-1

58 n consisting of the beta-lactamase inhibitor tazobactam and a fourth-generation cephalosporin, is und

59 She was treated with piperacillin-tazobactam and azithromycin and rapidly improved.

60 In summary, ceftolozane/tazobactam and ceftazidime/avibactam are 2 new second-ge

61 Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel beta-la

62 Both ceftolozane/tazobactam and ceftazidime/avibactam are only available

63 Both piperacillin-tazobactam and ceftriaxone inhibited colonization by an

64 The levels of enamine from tazobactam and clavulanic acid can be increased by incre

65 of class A beta-lactamase inhibitors such as tazobactam and clavulanic acid is the expression of vari

66 For tazobactam and clavulanic acid, the correctly oriented e

67 rum antimicrobial drugs such as piperacillin-tazobactam and drugs such as vancomycin for resistant pa

68 Data on the use of ceftolozane-tazobactam and emergence of ceftolozane-tazobactam resis

69 Since this property of piperacillin-tazobactam and galactomannan ELISA is not well understoo

70 The patient was treated with piperacillin-tazobactam and gentamicin.

71 was noted for the reformulated piperacillin-tazobactam and imipenem found on the AST-GN69 card, with

72 es toward false susceptibility (piperacillin-tazobactam and imipenem) and others toward false resista

73 ms to assess the association of piperacillin/tazobactam and meropenem minimum inhibitory concentratio

74 beta-lactamases than an equivalent amount of tazobactam and piperacillin.

75 The clinically used inhibitors tazobactam and sulbactam are effective in the inhibition

76 ibility testing performance for piperacillin/tazobactam and the high prevalence of OXA co-harboring E

77 The combination of piperacillin/tazobactam and tigecycline is safe, well tolerated, and

78 using ["vancomycin" and "piperacillin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nep

79 using ["vancomycin" and "piperacillin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nep

80 fepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment

81 ) bottles in removing meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam is unknown.

82 ma concentrations for meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

83 avancin, tedizolid, oritavancin, ceftolozane-tazobactam, and ceftazidime-avibactam.

84 ble concentrations of meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam.

85 antibiotics, such as meropenem, piperacillin/tazobactam, and cefuroxime, were not associated with suc

86 astatin, ceftazidime, cefepime, piperacillin/tazobactam, and ciprofloxacin.

87 proved beta-lactamase inhibitors: sulbactam, tazobactam, and clavulanate.

88 imipenem-ceftazidime, imipenem-piperacillin-tazobactam, and imipenem-cefoxitin.

89 ts (r values) for piperacillin, piperacillin-tazobactam, and meropenem were <0.80.

90 ined were vancomycin, cefepime, piperacillin/tazobactam, and meropenem.

91 while treatment with meropenem, piperacillin-tazobactam, and oral ciprofloxacin is associated with de

92 Tazobactam appears to form approximately twice as much e

93 Vancomycin and piperacillin-tazobactam are 2 of the most commonly prescribed antibio

94 Vancomycin and piperacillin-tazobactam are two of the most commonly prescribed antib

95 e ceftazidime, carbapenems, and piperacillin-tazobactam as definitive monotherapy.

96 n ceftazidime, carbapenems, and piperacillin-tazobactam as definitive treatment of P. aeruginosa bact

97 P) who received clindamycin and piperacillin-tazobactam as part of their treatment regime.

98 and efficacy of ertapenem with piperacillin/tazobactam as therapy following adequate surgical manage

99 We compared ceftriaxone and piperacillin-tazobactam at doses ranging from 0.1 to 2 times the huma

100 8%) received cefepime and (32%) piperacillin/tazobactam-based treatment.

101 impact on the microbiota, with piperacillin-tazobactam being particularly damaging.

102 When compared with our previously determined tazobactam-bound inhibitor structure, our new inhibitor-

103 inhibitors (clavulanic acid, sulbactam, and tazobactam), but the prevalence of inhibitor resistance

104 sa in bottles with cefepime and piperacillin-tazobactam, but the PF system recovered bacteria only in

105 After acylation of tazobactam by Ser(130) --> Gly, inactivation proceeds in

106 Piperacillin-tazobactam caused the most severe declines among obligat

107 fepime, Pseudomonas aeruginosa, piperacillin-tazobactam, cefepime, and gentamicin, Neisseria meningit

108 the adjusted hazards ratios for piperacillin/tazobactam, cefepime, and meropenem were 1.50 (95% CI: 1

109 Moreover, piperacillin, tazobactam, ceftazidime, and avibactam, as well as combi

110 Ceftolozane/tazobactam, ceftazidime/avibactam, and telavancin all ca

111 The piperacillin-avibactam and piperacillin-tazobactam-ceftazidime-avibactam combinations restored s

112 With in vivo validation, piperacillin-tazobactam-ceftazidime-avibactam may represent salvage t

113 e use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avib

114 itro, that in animals receiving piperacillin-tazobactam circulating galactomannan antigen accumulates

115 e beta-lactamase crystals are soaked in 5 mM tazobactam, clavulanic acid, and sulbactam solutions, re

116 n the setting of vancomycin and piperacillin-tazobactam co-administration.

117 n the setting of vancomycin and piperacillin-tazobactam coadministration.

118 nd hospital, IV vancomycin plus piperacillin/tazobactam combination therapy was associated with highe

119 who received IV vancomycin plus piperacillin/tazobactam combination therapy.

120 uous infusion of carbapenems or piperacillin/tazobactam compared to those receiving short-term (risk

121 ality for patients treated with piperacillin/tazobactam compared with meropenem was 9% (95% CI 3% - 1

122 volvement of a total of seven distinct GES-2.tazobactam complexes and one product of the hydrolysis o

123 Piperacillin-tazobactam consumption was the strongest predictor of th

124 mmunocompromised patients, only piperacillin-tazobactam contains significant amounts of galactomannan

125 acokinetics of antibiotics, but piperacillin-tazobactam continuous IV infusion pharmacokinetics has b

126 ps had decreased broad-spectrum piperacillin-tazobactam (control 56 hours, rmPCR 44 hours, rmPCR/AS 4

127 ories; adding not susceptible to ceftolozane-tazobactam could be even more predictive once AST for th

128 1.63 A resolution crystal structure revealed tazobactam covalently bound in the trans-enamine interme

129 % (4/518) of those who received piperacillin/tazobactam did not complete the assigned therapy due to

130 ted reliable activity, although piperacillin-tazobactam did not.

131 tatin/relebactam and 21.3% with piperacillin/tazobactam (difference, -5.3% [95% confidence interval {

132 The zone diameters for the ceftolozane-tazobactam disks were 23 to 29 mm for 92.2% of the isola

133 tio to receive intravenous 1.5 g ceftolozane-tazobactam every 8 h or intravenous high-dose (750 mg) l

134 ase gene was observed following piperacillin-tazobactam exposure and only in those strains that had u

135 in immunocompromised patients, piperacillin-tazobactam expressed a distinctively high level of galac

136 The ceftolozane-tazobactam failure rate was 29% (6/21).

137 m was noninferior (P < .001) to piperacillin/tazobactam for both endpoints: day 28 all-cause mortalit

138 rging data on the inefficacy of piperacillin-tazobactam for certain organisms that test susceptible,

139 and safety of ertapenem versus piperacillin/tazobactam for foot infections.

140 tudy of 21 patients treated with ceftolozane-tazobactam for MDR-P. aeruginosa infections.

141 h disk diffusion and MIC ranges for cefepime-tazobactam for multiple QC reference strains.

142 drug was added (ceftazidime or piperacillin/tazobactam for P. aeruginosa and vancomycin for methicil

143 004, that compared ertapenem to piperacillin-tazobactam for the treatment of moderate-to-severe diabe

144 , suggests using ceftazidime or piperacillin-tazobactam for treating susceptible infection.

145 The Raman data also indicated that tazobactam forms a larger population of enamine than sul

146 The results show that tazobactam forms a predominant population of trans-enami

147 ulfone and triazolyl groups that distinguish tazobactam from clavulanic acid and sulbactam, respectiv

148 visit 197 (54%) patients in the ceftolozane-tazobactam group and 194 (53%) in the meropenem group we

149 38 (11%) of 361 patients in the ceftolozane-tazobactam group and 27 (8%) of 359 in the meropenem gro

150 nd randomly assigned, 362 to the ceftolozane-tazobactam group and 364 to the meropenem group.

151 days, 87 (24.0%) patients in the ceftolozane-tazobactam group and 92 (25.3%) in the meropenem group h

152 Eight (2%) patients in the ceftolozane-tazobactam group and two (1%) in the meropenem group had

153 he ceftazidime, carbapenem, and piperacillin-tazobactam groups, respectively.

154 of thirteen patients receiving piperacillin-tazobactam had serum GMI values > 0.5 compared to none o

155 Patients (n = 13) receiving piperacillin-tazobactam had significantly greater mean serum GMI valu

156 A beta-lactamase with the sulfone inhibitor tazobactam have been trapped at 100 K and mapped by X-ra

157 tazidime (2 g every 8 hrs), and piperacillin/tazobactam have high probabilities of achieving adequate

158 For S130G reacted with tazobactam, identical steady state levels of enamine are

159 Susceptibilities to piperacillin-tazobactam, imipenem, meropenem, and trovafloxacin remai

160 e Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) wa

161 Klebsiella species) to 3.0 (for piperacillin-tazobactam in P. aeruginosa and Enterobacter species).

162 e, cefazolin, levofloxacin, and piperacillin-tazobactam in resin-containing BacT/Alert FN Plus and BD

163 reacts with clavulanic acid, sulbactam, and tazobactam in solution, but lacks the characteristic spe

164 In the case of S130G SHV, a structure of tazobactam in the active site has suggested that the inh

165 gested cefepime was superior to piperacillin-tazobactam in treating sepsis.

166 Piperacillin/tazobactam increased AKI risk, which was exacerbated by

167 16% in 2006 to 31% in 2010, and piperacillin-tazobactam increased from 16% to 27%, and there was a de

168 comycin, receipt of concomitant piperacillin-tazobactam increases the risk of nephrotoxicity.

169 with 16 g/2 g/24 hr continuous piperacillin-tazobactam infusion.

170 ast 0.5 times the HEDD, whereas piperacillin-tazobactam inhibited colonization at doses at least 0.75

171 Tazobactam inhibits the enzyme in a time-dependent manne

172 s (piperacillin susceptible and piperacillin-tazobactam intermediate; piperacillin intermediate and p

173 After intravenous infusion of piperacillin-tazobactam into rabbits, the serum galactomannan index (

174 Tazobactam is a clinically used inhibitor of class A bet

175 Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhib

176 ides a rationale for this finding since only tazobactam is able to form favorable intra- and intermol

177 ip with increased toxicity when piperacillin-tazobactam is added to vancomycin.

178 ip with increased toxicity when piperacillin-tazobactam is added to vancomycin.

179 High-dose ceftolozane-tazobactam is an efficacious and well tolerated treatmen

180 An acyclic form of tazobactam is covalently bonded to the catalytic Ser70 s

181 ally important beta-lactamases conclude that tazobactam is superior to both clavulanic acid and sulba

182 abilization of the transient intermediate of tazobactam is thought to contribute to tazobactam's supe

183 five-atom vinyl carboxylic acid fragment of tazobactam, is bonded to Ser130.

184 Treatment with ceftolozane-tazobactam led to better responses than high-dose levofl

185 The addition of 4 mug/ml tazobactam lowered the ceftolozane MIC50/MIC9(0)s to </=

186 racillin was similar to that to piperacillin-tazobactam (<1% difference) for 6,938 isolates of Entero

187 Concomitant vancomycin and piperacillin/tazobactam may be associated with increased acute kidney

188 nistration of IV vancomycin and piperacillin/tazobactam may increase the risk of AKI in hospitalized

189 us intermittent bolus dosing of piperacillin-tazobactam, meropenem, and ticarcillin-clavulanate condu

190 he cefepime-tazobactam QC ranges for a fixed tazobactam MIC of 8 mug/ml and disk diffusion (30/20-mug

191 %) after excluding strains with piperacillin/tazobactam MIC values > 16 mg/L.

192 s were associated with elevated piperacillin/tazobactam MICs and the highest risk increase in 30-mort

193 test susceptible, the value of piperacillin-tazobactam MICs is controversial.

194 ases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations >/=8 mug/mL

195 etronidazole (n = 12, P = .01), Piperacillin/Tazobactam (n = 52, P = .01), Meropenem/Vancomycin (n =

196 The piperacillin/tazobactam non-susceptible breakpoint (MIC > 16 mg/L) be

197 assess the independent impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI),

198 e, cefazolin, levofloxacin, and piperacillin-tazobactam on the recovery of Pseudomonas aeruginosa, Es

199 65 years), to receive either 3 g ceftolozane-tazobactam or 1 g meropenem intravenously every 8 h for

200 d receipt of IV vancomycin plus piperacillin/tazobactam or vancomycin plus 1 other antipseudomonal be

201 d with preferring cefepime over piperacillin/tazobactam (OR 1.14 95% CI [1.01-1.27], p = 0.03), (OR 1

202 cribed (cefepime, meropenem, or piperacillin-tazobactam) or had a positive culture isolating a Gram-n

203 Repeated administration of piperacillin-tazobactam over 7 days resulted in accumulation of circu

204 support the preferential use of ceftolozane/tazobactam over polymyxins or aminoglycosides for drug-r

205 the safety and effectiveness of piperacillin/tazobactam (P/T) in pediatric patients with hospital-acq

206 Piperacillin-tazobactam (P/T) is a beta-lactam-beta-lactamase inhibit

207 A series of cases of piperacillin-tazobactam (P/T)-associated neutropenia has been observe

208 m/cilastatin/relebactam and 267 piperacillin/tazobactam patients; 48.6% had ventilated HABP/VABP, 47.

209 astatin/relebactam and 32.0% of piperacillin/tazobactam patients; AEs leading to treatment discontinu

210 1 q8h or 4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no or

211 ve a high risk for CDI during a piperacillin/tazobactam (PIP/TAZO) shortage and hospital-onset Clostr

212 eracillin-avibactam, as well as piperacillin-tazobactam plus ceftazidime-avibactam (the clinically av

213 (23/24) and 88.5% (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, resp

214 Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropen

215 Ceftolozane/tazobactam plus metronidazole was noninferior to meropen

216 ast as effective as standard IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple tim

217 to 0.25 times the HEDD, whereas piperacillin-tazobactam promoted colonization at doses up to 0.5 time

218 l of the combinations, imipenem/piperacillin-tazobactam provided the greatest sensitivity (97.1%).

219 n at low risk for resistance to piperacillin-tazobactam (PT), cefepime (CE), and meropenem (ME).

220 The combination of piperacillin-tazobactam (PTZ) and vancomycin (VAN) has been identifie

221 The effectiveness of piperacillin-tazobactam (PTZ) for the treatment of extended-spectrum

222 Piperacillin-tazobactam (PTZ) is known to cause false-positive result

223 illin-clavulanic acid [AMC] and piperacillin-tazobactam [PTZ]) or carbapenem were compared in 2 cohor

224 The cefepime-tazobactam QC ranges for a fixed tazobactam MIC of 8 mug

225 respectively) suggest that fragmentation of tazobactam readily occurs in the inhibitor-resistant var

226 who do not need intensive care, piperacillin/tazobactam represents a regimen with an expected excelle

227 zane-tazobactam and emergence of ceftolozane-tazobactam resistance during multidrug resistant (MDR)-P

228 Ceftolozane-tazobactam resistance emerged in 3 (14%) patients.

229 The emergence of ceftolozane-tazobactam resistance in 3 patients is worrisome and may

230 sensitive for the detection of piperacillin-tazobactam resistance.

231 t; piperacillin susceptible and piperacillin-tazobactam resistant) accounted for 6.1% of the results

232 ; piperacillin intermediate and piperacillin-tazobactam resistant; piperacillin susceptible and piper

233 d 29 min for sulbactam, clavulanic acid, and tazobactam, respectively.

234 n sulbactam or clavulanic acid does and that tazobactam's intermediate is also the most long-lived.

235 a infections is needed to define ceftolozane-tazobactam's place in the armamentarium.

236 te of tazobactam is thought to contribute to tazobactam's superior in vitro and in vivo clinical effi

237 cephalosporins, aztreonam, and piperacillin-tazobactam seen across U.S. census regions.

238 with concomitant vancomycin and piperacillin/tazobactam should be considered when determining beta-la

239 (SHV-1, 0.14 microm; S130G, 46.5 microm) and tazobactam (SHV-1, 0.07 microm; S130G, 4.2 microm) were

240 on of IV vancomycin plus piperacillin sodium/tazobactam sodium is associated with a higher risk of ac

241 those for patients treated with piperacillin/tazobactam, suggesting that this once-daily antibiotic s

242 etween the beta-lactamase and the inhibitors tazobactam, sulbactam, and clavulanic acid are followed

243 Tazobactam, sulbactam, and clavulanic acid are the only

244 etween three clinically relevant inhibitors, tazobactam, sulbactam, and clavulanic acid, and SHV beta

245 is proposed that for small ligands, such as tazobactam, sulbactam, and clavulanic acid, the position

246 hibition by the mechanism-based inactivators tazobactam, sulbactam, and clavulanic acid.

247 ographic studies of S130G SHV inhibited with tazobactam, sulbactam, clavulanic acid, and 2'-glutaroxy

248 >90% of cases; however, against piperacillin/tazobactam, susceptibility was identified in <80% of cas

249 ta-lactamase inhibitors (i.e., sulbactam and tazobactam) than CMY-2.

250 mplexes and one product of the hydrolysis of tazobactam that contribute to the inhibition profile.

251 esistance against mecillinam or piperacillin-tazobactam that simultaneously confer full susceptibilit

252 e combination of vancomycin and piperacillin/tazobactam, the "workhorse" regimen at many institutions

253 In contrast to sulbactam and tazobactam, the reactions between oxacillin or 6alpha-hy

254 dime-avibactam is combined with piperacillin-tazobactam, the susceptibility of Bcc and B. gladioli to

255 , where he completed 4 weeks of piperacillin-tazobactam therapy.

256 Participants commenced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were r

257 aneous vancomycin, clindamycin, piperacillin-tazobactam, ticarcillin-clavulanic acid, metronidazole,

258 ecific antibiotics (vancomycin, piperacillin/tazobactam, tobramycin) further appear to correlate with

259 Ceftolozane-tazobactam (TOL-TAZ) affords broad coverage against Pseu

260 ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO).

261 ur previous structural studies that examined tazobactam trapped as a trans-enamine intermediate in a

262 f class A beta-lactamases PC1 and TEM-1 with tazobactam (TZB), a potent penicillanic sulfone inhibito

263 EI) vs intermittent infusion of piperacillin-tazobactam (TZP) and carbapenems on 30-day mortality of

264 The compound synergized with piperacillin-tazobactam (TZP) both in vitro and in vivo in a clinical

265 siella pneumoniae, resistant to piperacillin/tazobactam (TZP) but susceptible to carbapenems and 3rd

266 exist regarding the efficacy of piperacillin-tazobactam (TZP) for the management of non-bacteremic py

267 exist regarding the efficacy of piperacillin-tazobactam (TZP) for the management of nonbacteremic pye

268 to be uncertainty about whether piperacillin/tazobactam (TZP) increases the risk of AKI in critically

269 a multisite study evaluation of piperacillin-tazobactam (TZP) MIC testing on three U.S. Food and Drug

270 ctamase, our data are the first to show that tazobactam undergoes fragmentation while still attached

271 e combination antibacterial drug ceftolozane-tazobactam versus meropenem for treatment of Gram-negati

272 M error, 5.7%; m error, 13.5%), piperacillin-tazobactam (VM error, 9.3%; m error, 12.9%), ceftazidime

273 patients receiving vancomycin + piperacillin-tazobactam (VPT) compared to similar patients receiving

274 o treat for a clinical cure with ceftolozane/tazobactam was 5, and the number needed to harm with AKI

275 m, the use of ciprofloxacin and piperacillin/tazobactam was 51% and 75% higher than in the standard e

276 Concomitant vancomycin and piperacillin/tazobactam was associated with AKI in unadjusted (odds r

277 Piperacillin-tazobactam was associated with low abundance of potentia

278 uous infusion of carbapenems or piperacillin/tazobactam was associated with lower mortality.

279 Ceftolozane-tazobactam was discontinued in 1 patient (rash).

280 ences between groups, receipt of ceftolozane/tazobactam was independently associated with clinical cu

281 Ceftolozane-tazobactam was non-inferior to levofloxacin for composit

282 aeruginosa who were treated with ceftolozane/tazobactam was performed.

283 Piperacillin-tazobactam was prescribed more frequently to patients wi

284 In this small study, ceftolozane-tazobactam was successful in treating 71% of patients wi

285 Ceftolozane-tazobactam was thus non-inferior to meropenem in terms o

286 ntrast, susceptibility rates to piperacillin-tazobactam were 5.9 to 13.9% higher than to piperacillin

287 Patients who received ceftolozane/tazobactam were compared with those treated with either

288 Ertapenem and piperacillin-tazobactam were each active against >98% of the enteric

289 m, meropenem, piperacillin, and piperacillin-tazobactam were the most active since 51, 59, 51, 50, an

290 ime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested.

291 te in vitro activity evaluations of cefepime-tazobactam when tested against clinical Gram-negative ba

292 ) properties of carbapenems and piperacillin/tazobactam, when the duration of infusion is longer, wer

293 hanism-based inhibitor of beta-lactamases is tazobactam, which can function either irreversibly or in

294 Piperacillin-tazobactam, which has antienterococcal activity and is s

295 rts describe patients receiving piperacillin-tazobactam who were found to have circulating galactoman

296 the beta-lactamase inhibitor combination of tazobactam with the anti-pseudomonal cephalosporin cefto

297 e crystallographic structure of a complex of tazobactam with the Ser130Gly variant of the class A SHV

298 mine-like species are formed by sulbactam or tazobactam with this enzyme.

299 OR, 1.3; 95% CI, 0.67-2.51, for piperacillin-tazobactam, with carbapenems as reference in propensity

300 nd to the active site of wt SHV-1 similar to tazobactam yet forms an additional salt-bridge with K234